Auxly Cannabis Group Inc.
TSX:XLY.TO · Toronto Stock Exchange
+$0.00 today
Vol 3.79M · Avg 0.71M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
23.6%
avg -38.7%
ROIC
13.9%
avg -10.3%
ROA
15.4%
avg -17.0%
Analysis
ROE is currently the strongest return metric at 23.6% versus its period average of -38.7%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Hugo Alves | Chief Executive Officer & Director | $2.01M | — | 54 | — | — |
Michael David Lickver | President | $1.03M | — | 41 | — | — |
Travis Wong | Chief Financial Officer | $708,250.00 | — | — | — | — |
Vladimir Klacar | Senior Vice President of Operations | $708,250.00 | — | 37 | — | — |
Ron Fichter | General Counsel & Corporate Secretary | $674,000.00 | — | — | — | — |
Andrew MacMillan | Senior Vice President of Commercial | $347,800.00 | — | — | — | — |
Kevin Furet | Chief Cultivation & Genetics Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -26.3% | +7.9% (12yr)1 analysts |
| Revenue | N/A | N/A | -11.6% | +72.2% (12yr)1 analysts |
| Net Income | N/A | N/A | -32.4% | +67.5% (12yr)1 analysts |
| EBIT | N/A | N/A | -33.4% | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -11.6% over three years. Forward estimates point to Revenue at +72.2% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
NervGen Pharma Corp.
NGEN.V
$407.94M
CareRx Corporation
TSX:CRRX.TO
$203.03M
Cannara Biotech Inc.
LOVE.V
$181.03M
Cardiol Therapeutics Inc.
TSX:CRDL.TO
$171.76M
BioSyent Inc.
RX.V
$160.48M
Cybin Inc.
CYBN.NE
$157.82M
Grown Rogue International Inc.
GRIN.CN
$149.96M
HLS Therapeutics Inc.
TSX:HLS.TO
$133.86M
Jushi Holdings Inc.
JUSH.CN
$133.80M
Decibel Cannabis Company Inc.
DB.V
$69.23M
Who manages XLY.TO?
Auxly Cannabis Group Inc. (XLY.TO) lists 7 active executives. The top listed executive is Andrew MacMillan, Senior Vice President of Commercial.
Explore More
Continue the stock analysis
Jump to another research area for this company.